Real-world assessment of response to anti-programmed cell death 1 therapy in advanced cutaneous squamous cell carcinoma
Authors:
- 1 October 2021
- journal article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 85 (4) , 1038-1040
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI)British Journal of Cancer, 2020
- Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)Journal of Clinical Oncology, 2020
- Impact of corticosteroids on allograft protection in renal transplant patients receiving anti-PD-1 immunotherapyCancer Immunology, Immunotherapy, 2020
- Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literatureJournal for ImmunoTherapy of Cancer, 2019
- PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell CarcinomaNew England Journal of Medicine, 2018